Sage Therapeutics announced the upcoming commercial launch of ZURZUVAE for postpartum depression, and reported a strong financial foundation with $876 million in cash, cash equivalents and marketable securities as of September 30, 2023. Net revenue from sales of ZULRESSO was $2.7 million. The company expects operations to be supported into 2026, and annualized net savings of approximately $240 million from strategic reorganization.
ZURZUVAE approved for adults with PPD and designated Schedule IV by the DEA.
Expected wholesale acquisition cost of ZURZUVAE is $15,900.
SAGE-718 granted FDA Orphan Drug Designation for Huntington’s Disease.
Cash, cash equivalents and marketable securities totaled $876 million as of September 30, 2023.
Sage expects that its current cash, cash equivalents and marketable securities, along with anticipated funding from collaborations, collaboration revenue from sales of ZURZUVAE, and a potential milestone payment of $75.0 million from Biogen for the first commercial sale of ZURZUVAE for the treatment of women with PPD, will support operations into 2026. The company expects annualized net savings of approximately $240 million, of which 60% is related to R&D.
Analyze how earnings announcements historically affect stock price performance